文献速递临床试验与 GCP

帕罗西汀或喹硫平联合羟考酮与单用羟考酮对高碳酸血症通气反应的影响:一项随机临床试验

Effect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

该随机双盲交叉试验在健康参与者中比较帕罗西汀或喹硫平联合羟考酮与单用羟考酮对高碳酸血症通气反应的影响。结果显示帕罗西汀联合羟考酮在第1天和第5天显著降低通气反应,而喹硫平联合羟考酮无显著影响。作者结论为需进一步研究以明确长期治疗效应及临床相关性。

要点

  • 帕罗西汀联合羟考酮较单用羟考酮显著降低高碳酸血症通气反应。
  • 喹硫平联合羟考酮较单用羟考酮未显著降低高碳酸血症通气反应。
  • 帕罗西汀单用较安慰剂显著降低通气反应,喹硫平单用无显著影响。

核心结论

  • 在健康参与者中,帕罗西汀联合羟考酮较单用羟考酮显著降低第1天和第5天的高碳酸血症通气反应,而喹硫平联合羟考酮未产生此效应。
  • 作者结论指出需进一步研究以明确长期治疗后的效应及这些发现的临床相关性。

研究设计与样本

  • 随机、双盲、交叉临床试验,在威斯康星州西本德的一家临床药理学单位进行,纳入25名健康参与者,研究时间为2021年1月至2021年5月25日。
  • 干预措施:第1天和第5天给予羟考酮10 mg,并以随机顺序进行5天治疗:帕罗西汀40 mg每日一次、喹硫平每日两次(日剂量从100 mg增至400 mg)或安慰剂。
  • 主要结局:第1天和第5天采用重复呼吸法评估在呼气末二氧化碳为55 mm Hg时的通气量(高碳酸血症通气),比较帕罗西汀或喹硫平联合羟考酮与安慰剂联合羟考酮;次要结局:第4天比较帕罗西汀或喹硫平单用与安慰剂。

主要发现

  • 25名参与者(中位年龄35岁[IQR,30-40岁];11名女性[44%])中,19名(76%)完成试验。
  • 帕罗西汀联合羟考酮较安慰剂联合羟考酮的平均高碳酸血症通气在第1天显著降低(29.2 vs 34.1 L/min;平均差[MD],-4.9 L/min [单侧97.5%CI,-∞至-0.6];P=.01),第5天显著降低(25.1 vs 35.3 L/min;MD,-10.2 L/min [单侧97.5%CI,-∞至-6.3];P<.001)。
  • 喹硫平联合羟考酮较安慰剂联合羟考酮的平均高碳酸血症通气在第1天未显著降低(33.0 vs 34.1 L/min;MD,-1.2 L/min [单侧97.5%CI,-∞至2.8];P=.28),第5天未显著降低(34.7 vs 35.3 L/min;MD,-0.6 L/min [单侧97.5%CI,-∞至3.2];P=.37)。
  • 次要结局:第4天帕罗西汀单用较安慰剂的平均高碳酸血症通气显著降低(32.4 vs 41.7 L/min;MD,-9.3 L/min [单侧97.5%CI,-∞至-3.9];P<.001),喹硫平单用较安慰剂未显著降低(42.8 vs 41.7 L/min;MD,1.1 L/min [单侧97.5%CI,-∞至6.4];P=.67)。
  • 未报告药物相关严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者结论指出需进一步研究以明确长期治疗后的效应及这些发现的临床相关性。
  • 摘要中描述为初步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Opioids can cause severe respiratory depression by suppressing feedback mechanisms that increase ventilation in response to hypercapnia. Following the addition of boxed warnings to benzodiazepine and opioid products about increased respiratory depression risk with simultaneous use, the US Food and Drug Administration evaluated whether other drugs that might be used in place of benzodiazepines may cause similar effects. OBJECTIVE: To study whether combining paroxetine or quetiapine with oxycodone, compared with oxycodone alone, decreases the ventilatory response to hypercapnia. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, crossover clinical trial at a clinical pharmacology unit (West Bend, Wisconsin) with 25 healthy participants from January 2021 through May 25, 2021. INTERVENTIONS: Oxycodone 10 mg on days 1 and 5 and the following in a randomized order for 5 days: paroxetine 40 mg daily, quetiapine twice daily (increasing daily doses from 100 mg to 400 mg), or placebo. MAIN OUTCOMES AND MEASURES: Ventilation at end-tidal carbon dioxide of 55 mm Hg (hypercapnic ventilation) using rebreathing methodology assessed for paroxetine or quetiapine with oxycodone, compared with placebo and oxycodone, on days 1 and 5 (primary) and for paroxetine or quetiapine alone compared with placebo on day 4 (secondary). RESULTS: Among 25 participants (median age, 35 years [IQR, 30-40 years]; 11 female [44%]), 19 (76%) completed the trial. The mean hypercapnic ventilation was significantly decreased with paroxetine plus oxycodone vs placebo plus oxycodone on day 1 (29.2 vs 34.1 L/min; mean difference [MD], -4.9 L/min [1-sided 97.5% CI, -∞ to -0.6]; P = .01) and day 5 (25.1 vs 35.3 L/min; MD, -10.2 L/min [1-sided 97.5% CI, -∞ to -6.3]; P < .001) but was not significantly decreased with quetiapine plus oxycodone vs placebo plus oxycodone on day 1 (33.0 vs 34.1 L/min; MD, -1.2 L/min [1-sided 97.5% CI, -∞ to 2.8]; P = .28) or on day 5 (34.7 vs 35.3 L/min; MD, -0.6 L/min [1-sided 97.5% CI, -∞ to 3.2]; P = .37). As a secondary outcome, mean hypercapnic ventilation was significantly decreased on day 4 with paroxetine alone vs placebo (32.4 vs 41.7 L/min; MD, -9.3 L/min [1-sided 97.5% CI, -∞ to -3.9]; P < .001), but not with quetiapine alone vs placebo (42.8 vs 41.7 L/min; MD, 1.1 L/min [1-sided 97.5% CI, -∞ to 6.4]; P = .67). No drug-related serious adverse events were reported. CONCLUSIONS AND RELEVANCE: In this preliminary study involving healthy participants, paroxetine combined with oxycodone, compared with oxycodone alone, significantly decreased the ventilatory response to hypercapnia on days 1 and 5, whereas quetiapine combined with oxycodone did not cause such an effect. Additional investigation is needed to characterize the effects after longer-term treatment and to determine the clinical relevance of these findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04310579.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Florian J, van der Schrier R, Gershuny V, et al. Effect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial. JAMA. 2022. PMID: 36219407. doi:10.1001/jama.2022.17735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。